| Molecular Weight: | 346.65 |
| Formula: | C12H6ClF3N4O3 |
| Purity: | ≥98% |
| CAS#: | 1193383-09-3 |
| Solubility: | DMSO up to 100 mM |
| Chemical Name: | 1-(5-chloro-6-(trifluoromethoxy)-1H-benzo[d]imidazol-2-yl)-1H-pyrazole-4-carboxylic acid |
| Storage: | Powder: 4oC 1 year. DMSO: 4oC 3 month; -20oC 1 year. |
Biological Activity:
JNJ-42041935 is a potent and selective HIF-PHD inhibitor. It is a 2-OG competitive and reversible inhibitor for PHD enzymes (pKis = 7.91, 7.29, and 7.65 for PHD1, 2, and 3, respectively). It is >100-fold selective for PHD compared to the related FIH (factor-inhibiting HIF) and a panel of various other enzymes. In an inflammation-induced anemia model in rats, 100 µM/kg/day JNJ-42041935 significantly increased the number of circulating reticulocytes and red blood cells, increased blood hemoglobin and hematocrit, and restored mean corpuscular volume and mean cell hemoglobin of red bloods cells. JNJ-42041935 is a new pharmacological tool, which can be used to investigate PHD inhibition and demonstrate that PHD inhibitors offer great promise for the treatment of inflammation-induced anemia.
How to Use:
In vitro: JNJ-42041935 was used at 10 µM final concentration in vitro and in cellular assays.
In vivo: JNJ-42041935 was dosed to mice orally at 100 µM/kg once per day.
- 1. Barrett TD, et al. Pharmacological characterization of 1-(5-chloro-6-(trifluoromethoxy)-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (JNJ-42041935), a potent and selective hypoxia-inducible factor prolyl hydroxylase inhibitor. (2011) Mol Pharmacol. 79(6):910-20.
Products are for research use only. Not for human use.
